As of 12:20pm ET
| +0.09 / +1.81%|
Mesoblast Ltd. develops innovative cell based medicines. The company has leveraged its proprietary technology platform, which is based on mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.
|Silviu Itescu||Chief Executive Officer, Executive Director & MD|
|Paul Hodgkinson||Chief Financial Officer|
|Donna L. Skerrett||Chief Medical Officer|
|Jonathan Richard Symonds||Head-Corporate Finance & Strategy|
|Michael Schuster||Global Head-Investor Relations|